Merck’s implementation of artificial intelligence in drug research includes analyzing years of existing Merck clinical data to help identify which drugs and drug combinations to pursue. But Merck executive Matt Studney said AI is a tool to help, not replace humans.
Quibim’s technology applies artificial intelligence analysis to medical images to detect biomarkers. Hospitals and biopharma companies are among the startup’s customers, using its technology to analyze images to detect disease and guide clinical trial enrollment.
When it comes to managing inbound phone calls, underperformance has devastating cost implications.
China has become a key piece of Foresite Capital’s investment and company formation strategy. During the J.P. Morgan Healthcare Conference, Managing Director Michael Rome shared his thoughts on why biotech in China is booming as well as therapeutic areas where he sees promising science.
Combining AI-driven insights with tailored care pathways, patients gain access to health coaches, psychologists, and treatment plans, while providers benefit from workflow optimization.
At JPM25, Nvidia announced four new partnerships focused on scaling AI models across the healthcare industry. The company is teaming up with Mayo Clinic, Illumina, IQVIA and Arc Institute.
Healthcare AI company Innovaccer closed a $275 million Series F funding round, bringing its fundraising total to date to $675 million. The company has plans to go public “at some point,” but it isn’t in any hurry, said CEO Abhinav Shashank.
Mayo Clinic has developed a new tool that could speed up the time it takes for digital health companies to validate their tech to hospitals.
Many healthcare AI developers lack access to real-world data. To address this, Atropos Health is allowing AI developers to train and deploy their models using its real-world evidence network. The federated healthcare data network consists of more than 300 million patient records gathered from EHRs, claims data and patient registries.
Dr. Eric Topol pointed out that while initial findings on generative AI in clinical settings are promising, they may not withstand the complexities of real-world clinical practice.
President-elect Donald Trump recently appointed former Paypal executive David Sacks as the White House’s first-ever czar for AI and cryptocurrency. Ryan Tarzy — CEO of Avandra Imaging, a federated network for de-identified imaging data — thinks this appointment could help accelerate the pace of innovation in the healthcare industry.
Applications of SandboxAQ’s large quantitative models (LQMs) technology include running simulations that identify new biomarkers and optimize clinical development of drug candidates. The company spun out of Alphabet in 2022.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
BenevolentAI said it will still develop its internally discovered drugs, but will now seek partners for them earlier in their development. Going forward, BenevolentAI will focus on making its AI technologies available to support the drug R&D efforts of its partners.
In a recent report, Define Ventures revealed key insights from payers and providers on how they're shaping their AI strategies.
Vesalius Therapeutics’ AI-based technology finds novel targets and intervention points for subgroups of patients within a common disease. A small molecule that Vesalius has been developing for a novel Parkinson’s disease target is now headed to GSK, which has licensed global rights.
Jason Hill, Ochsner Health’s innovation officer, said he goes to sleep most nights and wakes up most morning worried about one thing: the state of generative AI governance in healthcare. To him, providers and other healthcare organizations are in dire need of frameworks to ensure their AI tools are safe and perform well over time.
During HLTH, I spoke with some investors and digital health executives about the types of startups that they haven’t encountered yet — but would like to.